Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļARTV
āļāļ·āđāļāļāļĢāļīāļĐāļąāļArtiva Biotherapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 19, 2024
āļāļĩāļāļĩāđāļAslan (Fred)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ89
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 19
āļāļĩāđāļāļĒāļđāđ5505 Morehouse Drive
āđāļĄāļ·āļāļSAN DIEGO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ92121
āđāļāļĢāļĻāļąāļāļāđ18582674467
āđāļ§āđāļāđāļāļāđhttps://www.artivabio.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļARTV
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 19, 2024
āļāļĩāļāļĩāđāļAslan (Fred)
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer and Compliance Officer
Chief Operating Officer, Chief Legal Officer and Compliance Officer
Ms. Elizabeth L. Hougen
Independent Director
Dr. Diego Miralles, M.D.
President, Head - Research and Development, Principal Financial Officer and Accounting Officer
President, Head - Research and Development, Principal Financial Officer and Accounting Officer
Dr. Laura Stoppel, Ph.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer